PXRB (PixarBio) Inventories, Work In Process : $0.00 Mil (As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Inventories, Work In Process?

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. PixarBio's work in process for the quarter that ended in Sep. 2016 was $0.00 Mil.

PixarBio Inventories, Work In Process Historical Data

The historical data trend for PixarBio's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Inventories, Work In Process Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Inventories, Work In Process

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Inventories, Work In Process	Get a 7-Day Free Trial					-	-	-	-	-

PixarBio Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

PixarBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Inventories, Work In Process

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.